Aelis Farma (XPAR:AELIS) Change In Receivables : €0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Aelis Farma Change In Receivables?

Aelis Farma's change in receivables for the quarter that ended in Dec. 2023 was €0.00 Mil. It means Aelis Farma's Accounts Receivable stayed the same from Jun. 2023 to Dec. 2023 .

Aelis Farma's change in receivables for the fiscal year that ended in Dec. 2023 was €-0.68 Mil. It means Aelis Farma's Accounts Receivable increased by €0.68 Mil from Dec. 2022 to Dec. 2023 .

Aelis Farma's Accounts Receivable for the quarter that ended in Dec. 2023 was €1.76 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Aelis Farma's Days Sales Outstanding for the six months ended in Dec. 2023 was 60.34.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Aelis Farma's liquidation value for the six months ended in Dec. 2023 was €8.49 Mil.

Aelis Farma Change In Receivables Historical Data

The historical data trend for Aelis Farma's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aelis Farma Change In Receivables Chart

Aelis Farma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-1.08

-0.68

Aelis Farma Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Receivables	Get a 7-Day Free Trial					-	-	-	-	-

Aelis Farma Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

Aelis Farma (XPAR:AELIS) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Aelis Farma's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	1.759	/	5.32	*	91
=	60.34

2. In Ben Graham's calculation of liquidation value, Aelis Farma's accounts receivable are only considered to be worth 75% of book value:

Aelis Farma's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	20.23	-	13.081	+	0.75 * 1.759	+	0.5 * 0.053
=	8.49

Aelis Farma Change In Receivables Related Terms

Thank you for viewing the detailed overview of Aelis Farma's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Aelis Farma (XPAR:AELIS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aelis Farma SA (XPAR:AELIS) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

69O:Germany

Address

146, rue Leo Saignat, Bordeaux, FRA, 33077

Website

https://www.aelisfarma.com

Aelis Farma SA is a biotechnology Company specializing in the research and development of treatment's related to brain diseases.

Aelis Farma (XPAR:AELIS) Headlines

No Headlines